Synthesis of (*R*)-(4-Methoxy-3,5-dihydroxyphenyl)glycine Derivatives: The Central Amino Acid of Vancomycin and Related Agents

Dale L. Boger,* Robert M. Borzilleri, and Seiji Nukui

Department of Chemistry, The Scripps Research Institute, 10666 North Torrey Pines Road, La Jolla, California 92037

Received January 12, 1996

Vancomycin (1)¹ was isolated in 1956 from *Streptomy*ces orientalis and its structure and stereochemistry were ultimately secured over 25 years later by a combination of chemical degradation,^{1b} NMR,^{1d,e} and X-ray crystallography studies.^{1f} This prototypic member of a large and growing class of clinically effective glycopeptide antibiotics²⁻⁴ which includes teicoplanin,^{2a} ristocetin,^{2b} β -avoparcin,^{2c} actaplanin (A4696),^{2d} and A33512B^{2e} is characterized by a polycyclic heptapeptide backbone composed of two 16-membered biaryl ether ring systems (CD and DE). Central to the characteristic bicyclic ring system is a (*R*)-(3,4,5-trihydroxyphenyl)glycine in which the meta 3,5-phenols form biaryl ethers to link the CD and DE rings. Herein, we report an asymmetric synthesis of **2–5** constituting selectively protected derivatives of (R)-(3,4,5-trihydroxyphenyl)glycine⁵ which have been utilized in our efforts⁶ on the development of synthetic approaches⁴ to vancomycin and related agents.

Key to the approach which complements the disclosed routes to the asymmetric synthesis of phenylglycines⁷ was the Sharpless asymmetric dihydroxylation⁸ of a substituted styrene for introduction of the α -center absolute stereochemistry as well as functionality for subsequent elaboration to the phenylglycine carboxylate. Following selective C4 *O*-methylation of methyl 3,4,5-trihydroxybenzoate as detailed by Pedro,⁹ the remaining C3 and C5 phenols were protected as benzyl ethers



(Scheme 1). Two-step conversion of the ester 6 to the aldehyde $\pmb{8}^{10}$ (95 \times 90%) and subsequent Wittig reaction with methylenetriphenylphosphorane provided the substituted styrene 9 (70%) and the key substrate for asymmetric dihydroxylation. Treatment of 9 with ADmix- α^{8} (1:1 *t*-BuOH/H₂O, 0.1 M, 25 °C, 20 h) provided **10** in superb conversions (97%) and high ee's (87% ee). The optical purity of **10** was assessed directly by chiral phase HPLC separation of the enantiomers on an analytical Diacel Chiralpak AD column (0.46×25 cm, 10% 2-propanol-hexane, 0.5 mL/min) alongside racemic material. The desired (S)-10 eluted with a retention time of 58.9 min and the enantiomer, (*R*)-10, eluted with a retention time of 55.1 min (ratio = 93.5:6.5). Following selective protection of the primary alcohol of 10 as its TBDMS ether 11, direct azide displacement of the secondary alcohol upon Mitsunobu activation (2.5 equiv of DPPA, 2.5 equiv of DEAD, THF, -20 to 25 °C, 2 h)¹¹ with clean inversion of stereochemistry and subsequent reduction of the crude azide 12 (2 equiv of Ph₃P, THF-H₂O, 45 °C, 21 h, 65% for two steps) provided the amine 13. Small amounts of elimination (7%) but no loss of the stereochemical integrity was observed during the displacement. N-CBZ protection of 13 provided 14 (90%), and deprotection of the TBDMS ether provided the key alcohol 15 (92%). The optical purity of 15 obtained directly from 10 without intervening recrystallizations was 84-87% ee indicating a maintenance of the stereochemical integrity throughout the sequence and of the crystalline intermediates, 15 proved to be the most convenient for storage, assessment, and enrichment of the optical purity. One recrystallization from 50% EtOAc-hexane routinely enriched the optical purity of **15** from 87% ee to \geq 94% ee. The optical purity of 15 was assessed on a Chiralpak AD HPLC column (0.46 × 25 cm, 30% 2-propanolhexane, 1.0 mL/min), (*R*)-15 $t_{\rm R}$ = 13.0 min and (*S*)-15 $t_{\rm R}$ = 7.9 min.

^{(1) (}a) McCormick, M. H.; Stark, W. M.; Pittenger, G. F.; Pittenger, R. C.; McGuire, G. M. Antibiot. Annu. **1955–1956**, 606. (b) Harris, C. M.; Kopecka, H.; Harris, T. M. J. Am. Chem. Soc. **1983**, 105, 6915. (c) Harris, C. M.; Harris, T. M. J. Am. Chem. Soc. **1982**, 104, 4293. (d) Williams, D. H.; Kalman, J. R. J. Am. Chem. Soc. **1977**, 99, 2768. (e) Williamson, M. P., Williams, D. H. J. Am. Chem. Soc. **1981**, 103, 6580. (f) Sheldrick, G. M.; Jones, P. G.; Kennard, O.; Williams, D. H.; Smith, G. A. Nature **1978**, 271, 223.

⁽f) Sheldrick, G. M.; Jones, P. G.; Kennard, G.; Williams, D. H., Shildi, G. A. *Nature* **1978**, *271*, 223.
(2) (a) Cornell, I. C.; Bardone, M. R.; Deparli, A.; Ferrari, P.; Tuan, G.; Gallo, G. G. *J. Antibiot.* **1984**, *37*, 621. (b) Harris, C. M.; Kibby, J. J.; Fehlner, J. R.; Raabe, A. B.; Barber, T. A.; Harris, T. M. *J. Am. Chem. Soc.* **1979**, *101*, 437. (c) McGahren, W. J.; Martin, J. H.; Morton, G. O.; Hargreaves, R. T.; Leese, R. A.; Lovell, F. M.; Ellestad, G. A.; O'Brien, E.; Holker, J. S. E. *J. Am. Chem. Soc.* **1980**, *102*, 1671. (d) Hunt, A. H.; Debono, M.; Merkel, K. E.; Barnhart, M. *J. Org. Chem.* **1984**, *49*, 635. (e) Debono, M.; Molloy, R. M.; Barnhart, M.; Dorman, D. E. *J. Antibiot.* **1980**, *33*, 1407.

⁽³⁾ Williams, D. H.; Rajananda, V.; Williamson, M. P.; Bojesen, G. *Top. Antibiot. Chem.* **1980**, *5*, 119. Barna, J. C. J.; Williams, D. H. *Annu. Rev. Microbiol.* **1984**, *38*, 339. Williams, D. H. *Acc. Chem. Res.* **1984**, *17*, 364. Williams, D. H.; Searle, M. S.; Westwell, M. S.; Mackay, J. P.; Groves, P.; Beauregard, D. A. *Chemtracts: Org. Chem.* **1994**, *7*, 133.

⁽⁴⁾ Rao, A. V. R.; Gurjar, M. K.; Reddy, K. L.; Rao, A. S. *Chem. Rev.* **1995**, *95*, 2135. Evans, D. A.; DeVries, K. M. *Drugs Pharm. Sci.* **1994**, *63*, 63.

⁽⁵⁾ Zhu, J.; Bouillon, J.-P.; Singh, G. P.; Chastanet, J.; Beugelmans, R. *Tetrahedron Lett.* **1995**, *36*, 7081.

⁽⁶⁾ Boger, D. L.; Borzilleri, R. M.; Nukui, S. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 3091. Boger, D. L.; Nomoto, Y.; Teegarden, B. R. *J. Org. Chem.* **1993**, *58*, 1425.

⁽⁷⁾ Williams, R. M.; Hendrix, J. A. Chem. Rev. 1992, 92, 889.

⁽⁸⁾ Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.* **1994**, *94*, 2483. Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K.-S.; Kwong, H.-L.; Morikawa, K.; Wang, Z.-M.; Xu, D.; Zhang, X.-L. *J. Org. Chem.* **1992**, *57*, 2768.

⁽⁹⁾ Cardona, M. L.; Fernandez, M. I.; Garcia, M. B.; Pedro, J. R. *Tetrahedron* **1986**, *42*, 2725.

⁽¹⁰⁾ Sethi, M. L.; Taneja, S. C.; Dhar, K. L.; Atal, C. K. *Indian J. Chem.* **1981**, *20B*, 770.

⁽¹¹⁾ Bansi, L.; Pramanik, B. N.; Manhas, M. S.; Bose, A. K. Tetrahedron Lett. 1977, 18, 1977.



Direct oxidation of the primary alcohol to the desired sensitive carboxylic acid **2** was accomplished best using *N*-oxoammonium salts¹² in combination with NaOCl in a buffered solution (2 equiv of 4-6% NaOCl, 1.1 equiv of TEMPO, 0.1 equiv of KBr, acetone-5% aqueous NaH-CO₃, 0 °C, 2 h, 78%). In the optimization of this reaction it was found that 1.1 equiv of TEMPO was necessary to obtain the desired oxidation product. If a catalytic amount (ca. 0.1 equiv) of TEMPO was employed or Ca-(OCl)₂¹³ was substituted for NaOCl, the chlorinated aromatic derivative 16 was isolated as the major product (eq 1). Presumably the TEMPO scavenges any chlorine which is liberated during the reaction. Similarly, propylene oxide could be utilized as the chlorine scavenger; however, the conversions to 15 were lower (40-50%). Using this optimized procedure, 2 could be obtained in good chemical yields (78%) with little or no racemization (94% ee). This could also be accomplished by conducting the oxidation in two separate steps without purification of the sensitive intermediate aldehyde by Dess-Martin oxidation (2 equiv, 30 min, CH₂Cl₂, 25 °C) followed by NaClO₂ treatment (9 equiv, 30% 0.7 M aqueous NaH₂-PO₄-*t*-BuOH, excess 2-methyl-2-butene, 25 °C, 20 min)

(12) (a) Anelli, P. L.; Biffi, C.; Montanari, F.; Quici, S. *J. Org. Chem.* **1987**, *52*, 2559. (b) Inokuchi, T.; Matsumoto, S.; Nishiyama, T.; Torri, S. *J. Org. Chem.* **1990**, *55*, 462. (c) Miyazawa, T.; Endo, T.; Shiihashi, S.; Okawara, M. *J. Org. Chem.* **1985**, *50*, 1332. which provided 2 in comparable chemical yields (75-77%) but with surprisingly little or no racemization (90-94% ee). Because of the ease of scale up, this latter procedure was used to routinely provide our material.¹³ In contrast, alcohol 15 underwent oxidation in the presence of PDC (4.5 equiv, DMF, 25 °C, 21 h) to provide 2 in only modest yields (20-30%) with extensive decomposition. Alternative oxidative conditions examined including RuCl₃ (0.2 equiv)-NaIO₄ (3 equiv, CCl₄-MeCN-H₂O, 3:1:1, 25 °C, 24 h) or Jones oxidation led to decomposition, and Pt/C (0.1 equiv)-O₂ (NaHCO₃, H₂Oacetone, 25 °C, 22 h) led to recovered starting material. Protection of **2** as its *tert*-butyl ester **3** (\geq 94% ee).¹⁴ which was selected over the methyl ester in order to minimize potential racemization when employed in subsequent synthetic efforts, followed by uneventful CBZ deprotection by hydrogenolysis provided 4. Similarly, CBZ deprotection of 2 followed by N-BOC protection of the free amino acid provided 5.



Experimental Section

Methyl 3,5-Dihydroxy-4-methoxybenzoate. This compound was prepared by the procedure reported:⁹ white needles, mp 147–148 °C (30% EtOAc–hexane), lit.¹⁵ mp 144–145 °C; ¹H NMR (DMSO- d_6 , 400 MHz) δ 9.50 (s, 1H), 6.96 (s, 2H), 3.82 (s, 3H), 3.75 (s, 3H); ¹³C NMR (DMSO- d_6 , 100 MHz) δ 166.1, 150.7, 139.7, 124.5, 108.5, 59.7, 51.9; IR (neat) ν_{max} 3386, 2996, 1709 cm⁻¹; FABHRMS (NBA–NaI) m/z 221.0430 (M⁺ + Na, C₉H₁₀O₅ requires 221.0426).

Methyl 3,5-Bis(benzyloxy)-4-methoxybenzoate (6). A solution of methyl 3,5-dihydroxy-4-methoxybenzoate (4.3 g, 22 mmol) in anhydrous DMF (25 mL) was sequentially treated with K₂CO₃ (11 g, 83 mmol) and PhCH₂Cl (6.5 mL, 57 mmol). The reaction mixture was warmed at 110 °C for 1 h, cooled to 25 °C, and quenched by the addition of H₂O (25 mL). The mixture was stirred for 15 min while the product precipitated. The resulting grey solid was collected by filtration and was washed with H_2O (3 \times 15 mL), dried in a vacuum desiccator, and purified by recrystallization from 20% EtOAc-hexane to afford 6 (7.5 g, 92%) as white needles: mp 116.5-118.0 °C (25% EtOAc-hexane), lit. mp 116-11810 and 118-119 °C;¹⁶ ¹H NMR (CDCl₃, 250 MHz) δ 7.50–7.31 (m, 12H), 5.17 (s, 4H), 3.95 (s, 3H), 3.89 (s, 3H); ¹³C NMR $(CDCl_3, 62.5 \text{ MHz}) \delta 166.5, 152.1 (2C), 143.5 (2C), 136.6,$ 128.5 (4C), 127.9 (2C), 127.3 (4C), 124.9, 109.1 (2C), 71.0 (2C), 60.9, 52.1; IR (neat) v_{max} 3019, 2933, 1717 cm⁻¹; FABHRMS (NBA-NaI) m/z 401.1373 (M⁺ + Na, C₂₃H₂₂O₅ requires 401.1365).

⁽¹³⁾ Nwaukwa, S. O.; Keehn, P. M. *Tetrahedron Lett.* **1982**, *23*, 35. Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155. Corey, E. J.; Kania, R. S. *J. Am. Chem. Soc.* **1996**, *118*, 1229 and references cited therein. Smith, A. B., III; Leenay, T. L. J. Am. Chem. Soc. **1989**, *111*, 5761.

⁽¹⁴⁾ Anderson, G. W.; Callahan, F. M. J. Am. Chem. Soc. 1960, 82, 3359.

⁽¹⁵⁾ Krauss, A. S.; Taylor, W. C. Aust. J. Chem. **1991**, 44, 1307.

⁽¹⁶⁾ Haslam, E.; Uddin, M. *Tetrahedron* 1968, 24, 4015.
(17) Degraw, J. I.; Christensen, J. C.; Brown, V. H.; Cory, M. J. J. *Heterocycl. Chem.* 1974, 11, 363.

This reaction has also been conducted on large scale with 115 g of $\bf{6}$ (92%) obtained from 65 g of starting phenol.

3,5-Bis(benzyloxy)-4-methoxybenzyl Alcohol (7). A cooled suspension of LiAlH₄ (1.2 g, 32 mmol) in anhydrous THF (30 mL) at 0 °C was treated dropwise with a solution of 6 (6.1 g, 16 mmol) dissolved in THF (25 mL). The resulting mixture was warmed to 25 °C, stirred for 40 min, and recooled to 0 °C before saturated aqueous NH₄Cl (10 mL) was added slowly. The reaction mixture was then filtered, and the remaining solid was washed with EtOAc (4 \times 15 mL). The volatiles were removed in vacuo, and the remaining residual white solid was purified by recrystallization from 50% EtOAchexane to afford 7 (5.4 g, 95%) as white prisms: mp 104.0-104.5 °C (40% EtOAc-hexane), lit. mp 104-105¹⁰ and 105–106 °C;¹⁷ ¹H NMR (CDCl₃, 250 MHz) δ 7.48– 7.32 (m, 10H), 6.64 (s, 2H), 5.11 (s, 4H), 4.52 (d, 2H, J =5.7 Hz), 3.90 (s, 3H); $^{13}\mathrm{C}$ NMR (CDCl_3, 62.5 MHz) δ 152.5 (2C), 138.5, 137.0 (2C), 136.5, 128.4 (4C), 127.8 (2C), 127.1 (4C), 106.2 (2C), 70.9 (2C), 65.1, 60.9; IR (neat) ν_{max} 3313, 3065, 3033, 2937 cm⁻¹; FABHRMS (NBA-NaI) m/z 373.1404 (M⁺ + Na, C₂₂H₂₂O₄ requires 373.1416). Anal. Calcd for C₂₂H₂₂O₄: C, 75.46; H, 6.33. Found: C, 75.67; H. 6.16.

This reaction has also been conducted on a large scale with 77 g of 7 (79%) obtained from 115 g of 6.

3,5-Bis(benzyloxy)-4-methoxybenzaldehyde (8). A solution of 7 (5.2 g, 15 mmol) in anhydrous CH_2Cl_2 (60 mL) was treated with activated MnO₂ (25 g) at 25 °C, and the resulting suspension was stirred for 2 h. The reaction mixture was filtered through a Celite pad (CH₂- Cl_2 , 5 × 50 mL), and the solvent was removed *in vacuo*. The crude residue was purified by recrystallization from 50% EtOAc-hexane to afford 8 (4.4 g, 90%) as a white powder: mp 85.5-87.5 °C (50% EtOAc-hexane), lit. mp 87–88¹⁰ and 85–88 °C;¹⁵ ¹H NMR (CDCl₃, 250 MHz) δ 9.79 (s, 1H), 7.49-7.33 (s, 10H), 7.18 (s, 2H), 5.19 (s, 4H), 3.99 (s, 3H); ¹³C NMR (CDCl₃, 62.5 MHz) δ 190.9, 152.9 (2C), 144.9, 136.4 (2C), 131.5, 128.7 (4C), 128.1 (2C), 127.3 (4C), 109.0 (2C), 71.1 (2C), 61.0; IR (neat) v_{max} 3064, 3032, 2939, 2830, 2731, 1693, 1587 cm⁻¹; FABHRMS (NBA–NaI) m/z 349.1435 (M⁺ + H, C₂₂H₂₀O₄ requires 349.1440). Anal. Calcd for C₂₂H₂₀O₄: C, 75.90; H, 5.79. Found: C, 76.17; H, 5.49.

This reaction has also been conducted on a large scale with PCC (CH_2Cl_2) with 64 g of **8** (85%) obtained from 77 g of **7**.

3,5-Bis(benzyloxy)-4-methoxystyrene (9). A suspension of methyltriphenylphosphonium bromide (12.3 g, 34.5 mmol) in anhydrous THF (70 mL) at -40 °C was treated with n-BuLi (1.9 M solution in hexane, 18.1 mL, 34.5 mmol) dropwise over 15 min, and the resulting solution was allowed to warm to -10 °C. After 40 min, the mixture was cooled to -30 °C and a solution of 8 (4.00 g, 11.5 mmol) in THF (7 mL) was added dropwise over 5 min. The resulting orange reaction mixture was warmed to 25 °C, stirred for 1.5 h, quenched by the addition of H_2O (40 mL), and extracted with EtOAc (4 \times 20 mL). The combined organic phases were washed with H_2O (2) \times 30 mL) and saturated aqueous NaCl (75 mL), dried (MgSO₄), and concentrated *in vacuo*. Chromatography (SiO₂, 4 \times 24 cm, 10–20% EtOAc-hexane gradient elution) afforded 9 (3.58 g, 90%) as white needles: mp 68.0-68.5 °C (20% EtOAc-hexane); ¹H NMR (CDCl₃, 250 MHz) δ 7.50–7.31 (m, 10H), 6.71 (s, 2H), 6.58 (dd, 1H, J = 10.8, 17.5 Hz), 5.58 (d, 1H, J = 17.5 Hz), 5.18 (d, 1H, J = 10.8 Hz), 5.16 (s, 4H), 3.92 (s, 3H); ¹³C NMR (CDCl₃,

62.5 MHz) δ 152.6 (2C), 140.1, 137.1, 136.5 (2C), 133.1, 128.5 (4C), 127.8 (2C), 127.2 (4C), 113.2, 106.1 (2C), 71.1 (2C), 61.0; IR (neat) ν_{max} 3033, 2938, 1580, 1505, 915, 842 cm⁻¹; FABHRMS (NBA–NaI) m/z 347.1662 (M⁺ + H, C₂₃H₂₂O₃ requires 347.1647). Anal. Calcd for C₂₃H₂₂O₃: C, 79.81; H, 6.40. Found: C, 80.10; H, 6.29.

1(S)-[3,5-Bis(benzyloxy)-4-methoxyphenyl]-2-hy**droxyethanol (10).** A stirred suspension of AD-mix- α^8 (Aldrich, 8.1 g, 1.4 g/mmol) in *t*-BuOH-H₂O (1:1, 58 mL) was treated with 9 (2.0 g, 5.8 mmol) at 25 °C, and the resulting two-phase reaction mixture was stirred vigorously at 25 °C for 20 h. Sodium sulfite (Na₂SO₃, 8.7 g, 1.5 g/mmol) was added, and the mixture was stirred for 30 min and diluted with EtOAc (50 mL). After separation of the layers, the aqueous phase was further extracted with EtOAc (3 \times 25 mL). The combined organic layers were washed with H₂O (50 mL) and saturated aqueous NaCl (50 mL), dried (MgSO₄), and concentrated in vacuo. The crude, white solid was purified by recrystallization from 50% EtOAc-hexane to afford 10 (2.1 g, 97%, 87% ee) as white needles: mp 103-104 °C (20% EtOAc-hexane); $[\alpha]^{25}_{D}$ +21 (*c* 1.0, CHCl₃); ¹H NMR (CDCl₃, 250 MHz) δ 7.44–7.28 (m, 10H), 6.61 (s, 2H), 5.07 (s, 4H), 4.61 (dd, 1H, J = 3.4, 7.8 Hz), 3.87 (s, 3H), 3.53 (ddd, 2H, J = 3.4, 7.8, 11.3 Hz), 3.05 (br s, 1H, OH), 2.48 (br s, 1H, OH); ¹³C NMR (CDCl₃, 62.5 MHz) δ 152.4 (2C), 138.6, 136.9 (2C), 136.2, 128.4 (4C), 127.8 (2C), 127.3 (4C), 105.4 (2C), 74.4, 70.9 (2C), 67.9, 60.8; IR (neat) ν_{max} 3386, 3066, 3033, 2933, 2871 cm⁻¹; FAB-HRMS (NBA–CsI) m/z 513.0661 (M⁺ + Cs, C₂₃H₂₄O₅ requires 513.0678). Anal. Calcd for C₂₃H₂₄O₅: C, 72.67; H, 6.36. Found: C, 72.56; H, 6.37.

1(S)-2-[(tert-Butyldimethylsilyl)oxy]-1-[3,5-bis(benzyloxy)-4-methoxyphenyl]ethanol (11). A solution of 10 (1.8 g, 4.7 mmol) in anhydrous DMF (20 mL) was treated with *t*-BuMe₂SiCl (0.86 g, 5.7 mmol) and imidazole (0.45 g, 6.6 mmol) at 0 °C under Ar. The resulting reaction mixture was warmed to 25 °C and stirred for 5 h before H₂O (40 mL) was added. The aqueous phase was extracted with EtOAc (3 \times 30 mL), and the combined extracts were washed with H₂O (75 mL), saturated aqueous NaCl (75 mL), dried (MgSO₄), and concentrated *in vacuo*. Flash chromatography (SiO₂, 5×25 cm, 10-20% EtOAc-hexane gradient elution) afforded **11** (2.0 g, 85%) as a colorless oil: $[\alpha]^{25}_{D}$ +12 (*c* 0.6, CHCl₃); ¹H NMR (CDCl₃, 250 MHz) & 7.48-7.28 (m, 10H), 6.66 (s, 2H), 5.14 (s, 4H), 4.60 (ddd, 1H, J = 2.0, 3.6, 8.1 Hz), 3.89 (s, 3H), 3.66 (dd, 1H, J = 3.6, 10.1 Hz), 3.44 (dd, 1H, J = 8.1, 10.1 Hz), 2.99 (d, 1H, J = 2.0 Hz), 0.94 (s, 9H), 0.08 (s, 6H); ¹³C NMR (CDCl₃, 62.5 MHz) δ 152.4 (2C), 138.9, 137.1 (2C), 135.7, 128.4 (4C), 127.7 (2C), 127.3 (4C), 105.9 (2C), 74.1, 71.0 (2C), 68.8, 60.8, 25.8 (3C), 18.2, -5.4 (2C);IR (film) ν_{max} 3475, 3064, 3032, 2952, 2927, 2856 cm⁻¹; FABHRMS (NBA-CsI) m/z 627.1570 (M⁺ + Cs, C₂₉H₃₈O₅-Si requires 627.1543).

1(*R*)-2-[(*tert*-Butyldimethylsilyl)oxy]-1-[3,5-bis(benzyloxy)-4-methoxyphenyl]ethylamine (13). A solution of **11** (0.94 g, 1.9 mmol) in anhydrous THF (14 mL) at -20 °C was treated sequentially with Et₃N (1.3 g, 4.8 mmol) diphenyl phosphorazidate (DPPA, 1.0 mL, 4.8 mmol), and diethyl azodicarboxylate (DEAD, 0.75 mL, 4.8 mmol). The reaction mixture was warmed to 25 °C, stirred for 2 h, and concentrated *in vacuo*. Chromatography (SiO₂, 4 × 24 cm, 5–10% EtOAc-hexane gradient elution) afforded 0.9 g of an inseparable 9:1 mixture of azide **12** and the corresponding elimination product, respectively, as a colorless oil which was carried on together into the subsequent step. For **12**: ¹H NMR (CDCl₃, 400 MHz) δ 7.46–7.31 (m, 10H), 6.55 (s, 2H), 5.12 (s, 4H), 4.42 (dd, 1H, J = 4.2, 8.3 Hz), 3.87 (s, 3H), 3.67 (dd, 1H, J = 4.2, 10.6 Hz), 3.61 (dd, 1H, J = 8.3, 10.6 Hz), 0.89 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 152.6 (2C), 139.4, 137.0 (2C), 132.3, 128.5 (4C), 127.9 (2C), 127.4 (4C), 106.8 (2C), 71.2 (2C), 68.3, 67.3, 60.9, 26.0 (3C), 18.3, -5.4 (2C); IR (film) ν_{max} 3065, 3032, 2928, 2857, 2099 cm⁻¹; MS (electrospray) m/z 542 (M⁺ + Na).

The mixture of azide **12** and the elimination product from the previous reaction (0.9 g) in THF (17 mL) was treated with Ph_3P (0.91 g, 3.5 mmol) and H_2O (0.31 mL, 0.017 mol) at 25 °C. The resulting reaction mixture was warmed at 45 °C for 21 h. The volatiles were removed in vacuo, and the residue was purified by flash chromatography (SiO_2, 4 \times 24 cm, 5–20% EtOAc–hexane gradient elution) to afford 13 (0.61 g, 65% based on starting alcohol **11**) and the elimination product (68 mg, 7%) as colorless oils. For **13**: $[\alpha]^{25}_{D}$ -9.7 (*c* 2.7, CHCl₃); ¹H NMR (CDCl₃, 400 MHz) δ 7.45–7.30 (m, 10H), 6.66 (s, 2H), 5.18 (s, 4H), 3.93 (dd, 1H, J = 3.9, 8.6 Hz), 3.87 (s, 3H), 3.57 (dd, 1H, J = 3.9, 9.8 Hz), 3.37 (dd, 1H, J =8.6, 9.8 Hz), 0.88 (s, 9H), 0.02 (s, 6H); ¹³C NMR (CDCl₃, 62.5 MHz) & 152.3 (2C), 138.5, 138.0, 137.1 (2C), 128.3 (4C), 127.7 (2C), 127.2 (4C), 106.4 (2C), 70.9 (2C), 69.4, 60.7, 57.5, 25.8 (3C), 18.2, -5.5 (2C); IR (film) ν_{max} 3383, 3064, 3032, 2953, 2928, 2856 cm⁻¹; FABHRMS (NBA-CsI) m/z 626.1723 (M⁺ + Cs, C₂₉H₃₉NO₄Si requires 626.1703).

For the elimination product: ¹H NMR (CDCl₃, 250 MHz) δ 7.54–7.32 (m, 10H), 6.77 (d, 1H, J = 12.1 Hz), 6.49 (s, 2H), 5.90 (d, 1H, J = 12.1 Hz), 5.15 (s, 4H), 3.90 (s, 3H), 0.96 (s, 9H), 0.20 (s, 6H); ¹³C NMR (CDCl₃, 62.5 MHz) δ 152.6 (2C), 141.9, 137.3 (2C), 133.8, 132.0, 128.5 (4C), 127.8 (2C), 127.2 (4C), 112.6, 105.2 (2C), 71.2 (2C), 61.0, 25.6 (3C), 18.3, -5.2 (2C); IR (film) ν_{max} 3032, 2953, 2928, 2857, 1758, 1645 cm⁻¹.

1(R)-N-[(Benzyloxy)carbonyl]-2-[(tert-butyldimethylsilyl)oxy]-1-[3,5-bis(benzyloxy)-4-methoxyphenyl]ethylamine (14). A solution of 13 (0.20 g, 0.41 mmol) in THF-H₂O (1:1, 4.0 mL) was treated with Na₂-CO₃ (86 mg, 0.81 mmol) and benzyl chloroformate (64 µL, 0.46 mmol) at 25 °C under Ar. After 2.5 h, the reaction mixture was poured into H₂O (10 mL) and extracted with EtOAc (4 \times 10 mL). The combined organic layers were washed with H_2O (3 \times 10 mL) and saturated aqueous NaCl (3×10 mL), dried (MgSO₄), filtered, and concentrated in vacuo. Chromatography (SiO₂, 3.5×10 cm, 10-25% EtOAc-hexane gradient elution) afforded **14** (0.22 g, 90%) as a white solid: mp 84.5–85.0 °C (20% EtOAc-hexane); $[\alpha]^{25}_{D}$ –15.2 (c 1.0, CHCl₃); ¹H NMR (CDCl₃, 400 MHz) δ 7.44–7.29 (m, 15H), 6.58 (s, 2H), 5.40 (d, 1H, NH, J = 7.4 Hz), 5.08 (s, 6H), 4.65-4.60 (m, 1H), 3.87 (s, 3H), 3.80 (dd, 1H, J = 4.0, 10.2 Hz), 3.65-3.58 (m, 1H), 0.88 (s, 9H), -0.08 (s, 3H), -0.10 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz), δ 156.4, 152.5 (2C), 138.6, 136.7 (2C), 134.0, 132.4, 128.4 (6 C), 128.0, 127.9 (2C), 127.4 (6C), 106.3 (2C), 71.0 (2C), 66.1, 66.7, 60.8, 56.6, 26.1 (3C), 18.5, -5.5 (2C); IR (neat) ν_{max} 3358, 3064, 3032, 2928, 2856, 1688, 1593, 1532 cm⁻¹; FAB-HRMS (NBA-CsI) m/z 760.2042 (M⁺ + Cs, C₃₇H₄₅NO₆-Si requires 760.2070). Anal. Calcd for C₃₇H₄₅NO₆Si: C, 70.84; H, 7.22; N, 2.23. Found: C, 70.66; H, 7.28; N, 2.21.

1(*R*)-*N*-[(Benzyloxy)carbonyl]-1-[3,5-bis(benzyloxy)-4-methoxyphenyl]-2-hydroxyethylamine (15). A solution of 14 (0.22 g, 0.36 mmol) in THF (5 mL) at 0 °C was treated dropwise with a 1.0 M solution of Bu_4NF in THF (0.43 mL, 0.43 mmol) under Ar. The resulting reaction mixture was warmed to 25 °C, stirred for 2 h, poured into H₂O (10 mL), and extracted with EtOAc (3 \times 10 mL). The combined organic extracts were washed with H₂O (20 mL), saturated aqueous NaCl (25 mL), dried (Na₂SO₄), and concentrated in vacuo. Flash chromatography (SiO₂, 3.5×10 cm, 20-50% EtOAc-hexane gradient elution) afforded 15 (0.17 g, 92%) as a white powder. Recrystallization (50% EtOAc-hexane) provided **15** (0.16 g, 88%, \geq 94% ee): mp 118–119 °C (50% EtOAc– hexane); [α]²³_D –21 (*c* 0.50, CHCl₃); ¹H NMR (CDCl₃, 400 MHz) & 7.42-7.29 (m, 15H), 6.52 (s, 2H), 5.40-5.36 (br s, 1H, NH), 5.09 (s, 6H), 4.69–4.64 (m, 1H), 3.89 (s, 3H), 3.78–3.74 (m, 2H), 1.78 (br s, 1H, OH); ¹³C NMR (CDCl₃, 100 MHz) & 156.3, 152.6 (2C), 138.6, 136.8 (2C), 136.1, 134.7, 128.4 (6C), 128.2, 127.9 (2C), 127.3 (6C), 106.1 (2C), 71.0 (2C), 66.8, 66.1, 60.8, 56.9; IR (neat) v_{max} 3332, 3041, 2950, 1685, 1595, 1535, 1509 cm⁻¹; FABHRMS (NBA-CsI) m/z 646.1229 (M⁺ + Cs, C₃₁H₃₁NO₆ requires 646.1206). Anal. Calcd for C₃₁H₃₁NO₆: C, 72.55; H, 6.08; N, 2.73. Found: C, 72.55; H, 6.11; N, 2.71.

(*R*)-*N*-[(Benzyloxy)carbonyl]-[3,5-bis(benzyloxy)-**4-methoxyphenyl]glycine (2).** Method A: A solution of 15 (84 mg, 0.16 mmol) in acetone (0.4 mL) at 0 °C was added to an aqueous 5% NaHCO₃ solution (0.4 mL), and additional acetone (ca. 0.4 mL), was added until stirring became possible. This heterogeneous mixture was treated sequentially with KBr (1.9 mg, 0.016 mmol) and TEMPO (28 mg, 0.18 mmol). Sodium hypochlorite (NaOCl, Aldrich 4-6% or *ca.* 0.5 M solution, 0.40 mL, 0.21 mmol) was added dropwise over 10 min, and the mixture was stirred at 0 °C. After 1 h, additional NaOCl (0.20 mL, 0.10 mmol) was added. The reaction mixture was stirred for 1 h before the addition of H₂O (10 mL), and EtOAc (10 mL). The aqueous phase was extracted with EtOAc $(3 \times 10 \text{ mL})$, and the combined organic layers were washed with H₂O (20 mL) and saturated aqueous NaCl (20 mL), dried (Na₂SO₄), and concentrated in vacuo. Chromatography (SiO₂, 3.5×10 cm, 2-10% CH₃OH-CHCl₃ gradient elution) afforded **2** (67 mg, 78%, \geq 94% ee)18 as a white solid: mp 128.5-130.0 °C (EtOHhexane); $[\alpha]^{25}_{D}$ -72 (c 1.0, CH₃OH); ¹H NMR (CD₃OD, 400 MHz) δ 7.45–7.16 (m, 15H), 6.75 (s, 2H), 5.05 (s, 1H), 4.99 (s, 2H), 4.96 (s, 4H), 3.67 (s, 3H); ¹³C NMR (CD₃OD, 100 MHz) & 173.8, 158.0, 153.9 (2C), 140.0, 138.4 (2C), 138.1, 134.2, 129.5 (6C), 129.0, 128.9 (2C), 128.8 (6C), 108.1 (2C), 72.0 (2C), 67.8, 61.3, 59.3; IR (neat) v_{max} 3316, 3016, 2937, 1717, 1592 cm⁻¹; FABHRMS (NBA-CsI) m/z660.1023 (M^+ + Cs, $C_{31}H_{29}NO_7$ requires 660.0998). Method B: A solution of 15 (56 mg, 0.11 mmol) in CH₂-Cl₂ (1.1 mL) at 0 °C was treated with Dess-Martin 12-I-5 periodinane reagent¹³ (92 mg, 0.22 mmol), and the resulting heterogeneous mixture was gradually warmed to 25 °C. After 30 min of stirring, the suspension was diluted with Et₂O (2 mL), poured into a saturated aqueous solution of NaHCO₃ (5 mL) containing Na₂S₂O₃-

⁽¹⁸⁾ The optical purity of **3** (94% ee) derived from **10** (87% ee) was assessed by chiral phase HPLC separation of the enantiomers on a Chiralpak AD HPLC column (0.46 × 25 cm, 30% 2-propanol-hexane, 1.0 mL/min) alongside racemic material, $t_{\rm R} = 13.0$ min for (*R*)-**3** and $t_{\rm R} = 21.0$ min for (*S*)-**3** (97:3), in which the enrichment of the optical purity (≥94% ee) was accomplished by recrystallization of intermediate **15**. Consequently, the optical purity of **2**, the precursor to **3**, following oxidation of **15** must be ≥94% ee. The optical purity of **4** (94% ee) was established upon conversion to the Mosher amide upon treatment with (-)-(*R*)-MTPC1 and ¹⁹F and ¹H NMR analysis alongside racemic material: ¹⁹F NMR (CDCl₃) δ -70.0 (3.0), -70.2 (97.0); ¹H NMR (CDCl₃, 400 MHz) δ 6.52 (s, 1.94), 6.39 (s, 0.06 H). Due to its chromatographic polarity, the optical purity of **5** was not assessed by chiral phase HPLC, but its use in subsequent efforts⁶ indicated that little or no racemization occurred in its preparation.

H₂O (0.19 g, 0.76 mmol), and stirred until two distinct layers were observed. The two layers were separated, and the aqueous phase was extracted with Et₂O (3 \times 7 mL). The combined organic extracts were washed with saturated aqueous NaHCO₃ (2×7 mL) and saturated aqueous NaCl (7 mL), dried (Na₂SO₄), and concentrated in vacuo to afford crude aldehyde (54 mg, 99%) which was sufficiently pure to use in the subsequent step. A buffered solution of NaClO₂ (Aldrich, 80%, 0.11 g, 0.99 mmol) and NaH₂PO₄ (0.10 g, 0.74 mmol) in H₂O (1 mL) was added dropwise to a solution of the aldehyde (54 mg, 0.11 mmol) in 2-methyl-2-butene (0.65 mL) and t-BuOH (2.6 mL, 1:4) at 25 °C. After stirring the reaction mixture for 20 min at 25 °C, the volatiles were removed in vacuo, and the residue was diluted with H_2O (10 mL) and extracted with EtOAc (3 \times 10 mL). The combined organic layers were dried (Na₂SO₄) and concentrated in *vacuo*. Flash chromatography (SiO₂, 2.5×10 cm, 5-10% $CH_3OH-CHCl_3$ gradient elution) afforded **2** (43 mg, 75%) over two steps) as a white solid: $[\alpha]^{25}_{D}$ -72 (*c* 0.9, CH₃-OH), $\geq 94\%$ ee).¹⁸

(R)-N-[(Benzyloxy)carbonyl]-[3,5-bis(benzyloxy)-2-chloro-4-methoxyphenyl]glycine (16). A solution of 15 (25 mg, 0.049 mmol) in acetone (0.2 mL) at 0 °C was added to an aqueous 5% NaHCO₃ solution (0.2 mL), and additional acetone was added (0.3 mL) until stirring became possible. This heterogeneous mixture was treated with TEMPO (0.08 mg, 0.005 mmol) followed by Ca(OCl)₂ (17 mg, 0.12 mmol). The resulting reaction mixture was stirred at 0 °C for 2 h, poured into H₂O (5 mL), and extracted with EtOAc (3×5 mL). The combined organic layers were washed with H₂O (10 mL) and saturated aqueous NaCl (20 mL), dried (Na₂SO₄), and concentrated in vacuo. Chromatography (SiO₂, 2.5×10 cm, 2-10%CH₃OH-CHCl₃ gradient elution) afforded 16 (14 mg, 52%) as a colorless oil: $[\alpha]^{25}_{D}$ –56 (*c* 0.025, CH₃OH); ¹H NMR (CD₃OD, 400 MHz) δ 7.38–7.14 (m, 15H), 6.89 (s, 1H), 5.60 (s, 1H), 4.98 (s, 2H), 4.95 (s, 2H), 4.90 (s, 2H), 3.72 (s, 3H); ¹³C NMR (CD₃OD, 100 MHz) δ 174.0, 158.1, 152.8 (2C), 150.3, 146.0, 138.5, 138.0 (2C), 132.5, 129.6 (2C), 129.5 (4C), 129.4 (2C), 129.2, 129.1 (2C), 129.0, 128.9 (2C), 111.0 (2C), 76.6 (2C), 72.2, 67.8, 61.7; IR (neat) $\nu_{\rm max}$ 3393, 1701, 1485, 1414, 1369, 1338, 1218, 1097 cm⁻¹; FABHRMS (NBA-CsI) m/z 694.0621 (M⁺ + Cs, C₃₁H₂₈-ClNO₇ requires 694.0609).

tert-Butyl (R)-N-[(Benzyloxy)carbonyl]-[3,5-bis-(benzyloxy)-4-methoxyphenyl]glycine (3). A sealed tube reaction vessel was charged with 2 (0.14 g, 0.27 mmol), anhydrous CH_2Cl_2 (2.7 mL), and concentrated H_2 -SO₄ (2.8 μ L, 0.053 mmol) at -15 °C. Before the tube was sealed, excess isobutylene gas was bubbled through the suspension until the volume tripled (9 mL, ca. 5 min). The reaction vessel was sealed, and the mixture was warmed to 25 °C and stirred for 24 h. The tube was then cooled to -78 °C, opened to the atmosphere, and allowed to slowly warm to 25 °C. N₂ was bubbled through the solution to remove the residual isobutylene. A 5% aqueous NaHCO₃ solution (10 mL) and EtOAc (10 mL) were added and the mixture was extracted with EtOAc $(3 \times 10 \text{ mL})$. The combined organic phases were washed with 5% aqueous NaHCO₃ (20 mL) and saturated aqueous NaCl (20 mL), dried (Na₂SO₄), and concentrated in vacuo. Chromatography (SiO₂, 3.5×10 cm, 10-40%EtOAc-hexane gradient elution) afforded 3 (0.13 g, 87%, 94% ee¹⁸) as a white film: $[\alpha]^{25}_{D}$ -60 (*c* 1.3, CHCl₃); ¹H NMR (CDCl₃, 400 MHz) & 7.44-7.25 (m, 15H), 6.64 (s, 2H), 5.78 (d, 1H, NH, J = 7.2 Hz), 5.12 (s, 1H), 5.10 (s, 4H), 5.09 (s, 2H), 3.90 (s, 3H), 1.32 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ 169.6, 155.3, 152.7 (2C), 139.3, 136.9 (2C), 136.2, 132.7 (2C), 128.5 (6C), 128.2 (2C), 127.9 (4C), 127.3 (2C), 106.5 (2C), 82.7, 71.0 (2C), 67.0, 60.9, 58.3, 27.8 (3C); IR (film) $\nu_{\rm max}$ 3346, 3056, 2978, 2929, 1721, 1529 cm⁻¹; FABHRMS (NBA–CsI) m/z 716.1604 (M⁺ + Cs, C₃₅H₃₇NO₇ requires 716.1624).

tert-Butyl (*R*)-(3,5-Dihydroxy-4-methoxyphenyl)glycine (4). A solution of 3 (0.13 g, 0.22 mmol) in CH₃-OH (2.5 mL) at 25 °C was treated with 10% Pd–C (13 mg) and was stirred under 1 atm of H₂ for 5 h. The reaction mixture was filtered through a pad of Celite (10% CH₃OH–CHCl₃, 3 × 10 mL), and the solvent was removed *in vacuo*. Chromatography (SiO₂, 3.5 × 10 cm, 5–10% CH₃OH–CHCl₃ gradient elution) afforded **4** (59 mg, 98%) as a white film: $[\alpha]^{25}_{\rm D}$ –53 (*c* 0.27, CH₃OH);¹⁸ ¹H NMR (CD₃OD, 400 MHz) δ 6.24 (s, 2H), 4.07 (s, 1H), 3.64 (s, 3H), 1.30 (s, 9H); ¹³C NMR (CD₃OD, 100 MHz) δ 172.2, 149.9 (2C), 135.3, 134.5, 105.2 (2C), 80.6, 58.8, 57.8, 26.1 (3C); IR (neat) $\nu_{\rm max}$ 3349, 3269, 2958, 2912, 1712, 1560, 1523 cm⁻¹; FABHRMS (NBA–NaI) *m/z* 292.1156 (M⁺ + Na, C₁₃H₁₉NO₅ requires 292.1161).

(*R*)-*N*-[(*tert*-Butyloxy)carbonyl]-(3,5-dihydroxy-4methoxyphenyl)glycine (5). A solution of 2 (45 mg, 0.085 mmol) in CH₃OH (0.9 mL) at 25 °C was treated with 10% Pd-C (4.5 mg, 0.10 wt equiv), and the mixture was stirred under 1 atm of H₂ for 8 h. The reaction mixture was filtered through a pad of Celite (CH₃OH, 50 mL), the solvent was removed *in vacuo*, and the product was dried under vacuum to afford the deprotected amino acid (18 mg, 0.085 mmol) which was used directly in the following reaction.

A solution of the amino acid (18 mg, 0.085 mmol) in THF-H₂O (1:1, 1.7 mL) was treated with NaHCO₃ (22 mg, 0.26 mmol) and di-tert-butyl dicarbonate (41 mg, 0.19 mmol) at 25 °C under Ar. After 10 h, aqueous citric acid (pH = 3-4, 1.7 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (2×10 mL). The combined organic layers were washed with saturated aqueous NaCl (1 \times 2 mL), dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Chromatography (SiO₂, 3×14 cm, CH₂Cl₂-CH₃OH-HOAc 88:10:6) afforded 5 (22 mg, 78%) as a white film: $[\alpha]^{25}_{D}$ -89 (*c* 0.8, CH₃OH);¹⁸ ¹H NMR (CD₃OD, 400 MHz) δ 6.41 (s, 2H), 4.92 (s, 1H), 3.76 (s, 3H), 1.43 (s, 9H); 13 C NMR (CD₃OD, 100 MHz) δ 175.3, 157.3, 151.8, 136.5, 135.1, 107.8, 80.6, 60.7, 28.7, 28.5; IR (neat) v_{max} 3345, 2976, 2932, 1694, 1600, 1504, 1455, 1161 cm⁻¹; FABHRMS (NBA-NaI) m/z 336.1069 (M⁺ + Na, C₁₄H₁₉NO₇ requires 336.1059).

Acknowledgment. We gratefully acknowledge the financial support of the National Institutes of Health (CA41101) and the award of a NIH postdoctoral fellow-ship (RMB, GM17548), and we wish to thank Professor Sharpless for use of the Diacel Chiralpak AD HPLC column.

Supporting Information Available: ¹H NMR spectra of **6**, **11**, **13**, **16**, and **2**–**5** are provided (8 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

JO960085F